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Abstract
Introduction This report describes the isolation and
characterization of three new murine mammary epithelial cell
lines derived from mammary tumors from MMTV (mouse
mammary tumor virus)/activated Neu + TβRII-AS (transforming
growth factor [TGF]-β type II receptor antisense RNA) bigenic
mice (BRI-JM01 and BRI-JM05 cell lines) and MMTV/activated
Neu transgenic mice (BRI-JM04 cell line).
Methods The BRI-JM01, BRI-JM04, and BRI-JM05 cell lines
were analyzed for transgene expression, their general growth
characteristics, and their sensitivities to several growth factors
from the epidermal growth factor (EGF) and TGF-β families
(recombinant human EGF, heregulin-β1 and TGF-β1). The BRI-
JM01 cells were observed to undergo a striking morphologic
change in response to TGF-β1, and they were therefore further
investigated for their ability to undergo a TGF-β-induced
epithelial-to-mesenchymal transition (EMT) using motility assays
and immunofluorescence microscopy.
Results We found that two of the three cell lines (BRI-JM04 and
BRI-JM05) express the Neu transgene, whereas, unexpectedly,
both of the cell lines that were established from MMTV/activated
Neu + TβRII-AS bigenic tumors (BRI-JM01 and BRI-JM05) do
not express the TβRII-AS transgene. The cuboidal BRI-JM01
cells exhibit a short doubling time and are able to form confluent
monolayers. The BRI-JM04 and BRI-JM05 cell lines are
morphologically much less uniform, grow at a much slower rate,
and do not form confluent monolayers. Only the BRI-JM05 cells
can form colonies in soft agar. In contrast, all three cell lines form
colonies in Matrigel, although the BRI-JM04 and BRI-JM05 cell
lines do so more efficiently than the BRI-JM01 cell line. All three
cell lines express the cell surface marker E-cadherin, confirming
their epithelial character. Proliferation assays showed that the
three cell lines respond differently to recombinant human EGF
and heregulin-β1, and that all are growth inhibited by TGF-β1, but
that only the BRI-JM01 cell line undergoes an EMT and exhibits
increased motility upon TGF-β1 treatment.
Conclusion We suggest that the BRI-JM04 and BRI-JM05 cell
lines can be used to investigate Neu oncogene driven mammary
tumorigenesis, whereas the BRI-JM01 cell line will be useful for
studying TGF-β1-induced EMT.
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Introduction
An understanding of the molecular mechanisms that under-
lie the neoplastic transformation of breast epithelial cells is
dependent upon the isolation of relevant continuous cell
culture systems that model breast carcinogenesis and pro-
gression. Because transforming growth factor (TGF)-β iso-
forms are pleiotropic polypeptides that play complex roles
in tumorigenesis, it is of particular interest to isolate cell
lines with responses to TGF-β that reflect various aspects
of this complexity.
The ability of TGF-β to inhibit cell proliferation, induce rep-
licative senescence and apoptosis, and maintain genomic
stability suggests that it should play a role as a tumor sup-
pressor [1]. Indeed, in a subset of human cancers, in par-
ticular those of the gastrointestinal tract, inactivating
ALK = activin receptor-like kinase; AS = antisense RNA; DMEM = Dulbecco's modified Eagles medium; dn = dominant negative; EGF= epidermal 
growth factor; EMT = epithelial-to-mesenchymal transition; FBS = fetal bovine serum; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; HRG 
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mutations in the TGF-β receptors or Smad signal transduc-
tion molecules have been observed [2]. However, in most
other cancers genetic inactivation of TGF-β receptors or
downstream effectors appears to be rare. A reduction in
TGF-β r e c e p t o r s ,  r a t h e r  t h a n  a  l o s s ,  i s  m o r e  c o m m o n l y
observed. For example, reduced expression of TGF-β type
II receptor (TβRII) correlated with high tumor grade within
both human breast in situ and invasive carcinomas, and has
been associated with an increased risk for invasive breast
cancer in women with breast epithelial hyperplastic lesions
that lack atypia [3,4]. The observation that TGF-β signaling
is rarely completely lost in tumors led to the suggestion that
retention of some TGF-β responses may actually be advan-
tageous for tumor cells. The biologic activities of TGF-β
that could promote tumor progression include its ability to
enhance tumor cell invasiveness and migration, and to
inhibit immune surveillance. The clinical significance of
these tumor promoting effects was recently highlighted by
two reports [5,6] that showed that a TGF-β antagonist
based on a soluble receptor ectodomain could effectively
reduce tumor metastasis. The current unifying hypothesis,
therefore, is that TGF-β switches from acting as a tumor
suppressor to a prometastatic factor during the course of
multistage tumor progression [1,2,7-9].
When epithelial cancer cells metastasize, they must leave
the primary tumor, invade the surrounding tissue, enter the
bloodstream, and disseminate to secondary sites. The ini-
tial steps in this process involve loss of epithelial cell polar-
ity, dissolution of cell–cell contacts, and acquisition of
increased cell motility [10-12] – a process commonly
referred to as epithelial-to-mesenchymal transition (EMT).
This tumor cell transition resembles, but is not identical to,
the phenomenon that occurs when cells of epithelial origin
migrate during embryonic morphogenesis [13]. It has been
observed that TGF-β stimulation of both nontransformed
and tumor-derived cell lines can induce an EMT in culture
[14-18]. Study of these cells has implicated several signal-
ing pathways in TGF-β-induced EMT, including Smads,
RhoA, phosphoinositide-3 kinase/Akt and p38 mitogen-
activated protein kinase (MAPK) [19,20]. Experiments
using Tβ RI mutants that fail to bind Smads have demon-
strated that some of these pathways, such as the p38
MAPK pathway, are Smad independent; however, the over-
all EMT process does require Smad signaling [21].
In relation to studying the role of the TGF-β-induced EMT in
breast cancer progression in particular, the nontrans-
formed NMuMG and EpH4 mouse mammary epithelial cell
lines are the most commonly used models. Both lines are
growth inhibited and undergo EMT when exposed to TGF-
β. However, the EMT response of the EpH4 cell line to
TGF-β requires the expression of Ras variants that induce
hyperactivation of the extracellular signal-regulated kinase/
MAPK pathway [22,23]. Therefore, isolation of additional
mammary epithelial cell culture systems that respond to
TGF-β with a conspicuous EMT is required in order to elu-
cidate further the pathways that underlie this process.
To investigate the effect of reduced TGF-β signaling on
mammary gland development and tumorigenesis, we gen-
erated a transgenic mouse model that expressed a TβRII-
antisense RNA (AS) under the control of the mouse mam-
mary tumor virus (MMTV) promotor. These transgenic ani-
mals exhibited precocious lobuloalveolar development of
the mammary gland, a phenotype resembling early preg-
nancy, but no associated mammary tumor development,
even at an age of over 20 months [24]. Similar observations
were made in two transgenic mouse lines expressing a
dominant negative (dn)TβRII in the mammary gland,
although in one of these lines spontaneous mammary
tumors were observed between 17 and 29 months of age
[25,26].
Overexpression of the ErbB-2/Neu oncogene is associated
with malignancy and poor prognosis in breast cancer [27-
30]. To study the interplay between ErbB-2/Neu and TGF-
β signaling in mammary tumor occurrence and progression,
we have now generated a bigenic mouse model in which
the MMTV/TβRII-AS RNA is expressed together with an
activated Neu receptor, also under the control of the MMTV
promotor (MMTV/activated Neu). To date, we have found
no significant difference in the latency of primary tumor for-
mation in these bigenic mice as compared with mice
expressing the activated Neu oncogene alone (Lenferink
AEG and coworkers, unpublished data). However, recently,
in related bigenic mouse models in which a dnTβRII was
coexpressed with forms of the Neu receptor that selectively
couple to different signaling pathways, a decreased latency
of Neu-induced mammary tumor formation was observed
[31]. The finding that TβRII-AS RNA expression appears to
have less effect on both spontaneous and Neu-induced
tumor formation, as compared with dnTβRII expression,
may indicate that the dnTβRII blocks signaling from other
TGF-β superfamily members by interacting with the cog-
nate type I receptors for these ligands. The ability of a dnT-
βRII to block more than one TGF-β superfamily member has
recently been confirmed in MDA-MB-231 cells [8].
To provide breast tumor epithelial cell lines in which the
interplay between TGF-β and activated Neu signaling may
be studied, and in which TGF-β signaling may be specifi-
cally reduced but not eliminated due to TβRII-AS RNA
expression, we established cell lines from tumors from both
our MMTV/activated Neu + TβRII-AS bigenic mice and the
MMTV/activated Neu transgenic mice. In this report we
present the characterization of these cell lines, including
analyses of the expression of the Neu and TβRII-AS trans-
genes, of the expression of epithelial markers, and of their
responses to TGF-β and ligands that signal through ErbBAvailable online http://breast-cancer-research.com/content/6/5/R514
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receptors. In two out of three cell lines, Neu oncogene
expression was maintained. Expression of the TβRII-AS
transgene was not maintained in any of the cell lines. Most
significantly, we found that one of the cell lines undergoes
a striking EMT in response to TGF-β. This cell line will pro-
vide an additional in vitro model system for the investigation
of the mechanisms and pathways that underlie TGF-β-
induced EMT in mammary epithelial cells.
Methods
Antibodies, reagents, and cell lines
Mouse monoclonal β-catenin and N-cadherin antibodies
were purchased from Transduction Laboratories (Missis-
sauga, ON, Canada), a monoclonal E-cadherin antibody
(anti-uvomorulin clone Decma-1) was purchased from
Sigma (Oakville, ON, Canada), and monoclonal anti-ZO-1
and anti-vimentin antibodies were obtained from Chemicon
International (Temecula, CA, USA) and ICN Biochemicals
Inc. (Irvine, CA, USA), respectively. Polyclonal ErbB-1,
ErbB-2, ErbB-3, and ErbB-4 antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), a
monoclonal ErbB-2/Neu antibody was obtained from Neo-
Markers (Fremont, CA, USA), and a monoclonal anti-phos-
pho-tyrosine antibody (clone 4G10) was purchased from
Upstate Biotechnology (Charlottesville, VA, USA). Horse-
radish peroxidase conjugated secondary antibodies were
obtained from Jackson Immuno Research Laboratories Inc
(West Grove, PA, USA). Texas-red conjugated anti-rat and
anti-mouse antibodies, Texas-red conjugated fungal toxin
phalloidin, and Alexa-488 goat-anti-rat conjugates were
purchased from Molecular Probes (Eugene, OR, USA). The
FITC-conjugated anti-goat antibody was obtained from
Santa Cruz Biotechnology and the rat anti-HA antibody
was purchased from Boehringer-Ingelheim (Burlington,
ON, Canada). Recombinant human epidermal growth fac-
tor (EGF) was obtained from Austral Biologicals (San
Ramon, CA, USA), heregulin (HRG)-β1 from NeoMarkers,
and recombinant human TGF-β1 and TGF-β2 were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Mink lung cells (Mv1Lu) were obtained from the American
Tissue Culture Collection (ATCC; Mannasas, VA, USA)
and routinely cultured in Dulbecco's modified Eagles
medium (DMEM; Wisent Inc., St.-Bruno, QC, Canada) sup-
plemented with 10% fetal bovine serum (FBS; HyClone
Laboratories Inc., Logan, UT, USA). Murine myeloma NS0
cells (a kind gift from C Guilbault) were maintained in
DMEM/NCTC 109 medium (4:1; vol/vol) containing 10%
FBS. All cell lines were cultured at 37°C in a humidified 5%
carbon dioxide atmosphere.
Isolation and in vitro culture of mammary tumor 
epithelial cell lines
FVB control and FVB MMTV/activated Neu transgenic
mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). C3H×C57Bl/6 mice expressing
MMTV/TβRII-AS [25] were backcrossed eight times with
FVB mice and then interbred to generate mice expressing
the MMTV/TβRII-AS on a congenic FVB background.
These mice were mated with FVB MMTV/activated Neu
transgenic animals to generate FVB MMTV/activated Neu
+ TβRII-AS bigenic animals. All offspring were screened for
transgene expression by PCR using genomic mouse tail
DNA. Neu (5'-GAAGGCACTGCCTCTCCGC-3') and
TβRII-AS (5'-TTGTGGTTGATGTTGTTGG-3') specific
primers were both used in combination with a polyadenyla-
tion signal specific primer (5'-CTCTGTAGGTAGTTT-
GTCC-3'), applying the following conditions: 94°C for 1
min; 34 cycles of 94°C for 30 s, 48°C (TβRII-AS) or 55°C
(Neu) for 30 s, and 72°C for 1 min; followed by 72°C for 2
min.
Immediately after weaning, virgin MMTV/activated Neu and
MMTV/activated Neu + TβRII-AS expressing female off-
spring were palpated twice a week for tumor formation.
Mammary tumors were harvested, washed twice in ice-cold
phosphate-buffered saline (PBS; Wisent Inc), cut into small
pieces and incubated in trypsin/EDTA (Wisent Inc.) at 4°C
for 30 min, while rocking. Cell suspensions were washed
twice with ice-cold PBS, and resuspended in a mixture of
DMEM and Ham's F12 (1:1) supplemented with 5% FBS
and antibiotics/antimycotics (Wisent Inc.). The cells were
further propagated in this medium, which is subsequently
referred to as DF/5% unless otherwise stated.
The BRI-JM01 and BRI-JM04 cell lines were isolated by
harvesting nonadherent cells 3 hours after plating the
tumor suspension. These nonadherent cells were then
reseeded and cultured for 3 days. Clusters of epithelial
cells were then isolated and transferred to a 24-well plate
for further propagation. The BRI-JM05 cell line was estab-
lished by seeding the tumor cell suspension in growth fac-
tor reduced Matrigel without phenol red (Beckton
Dickinson, San Jose, CA, USA). Cells were maintained in
Matrigel until 'tree-like' structures appeared, which were
then recovered using MatriSperse (Beckton Dickinson),
rinsed twice with ice-cold PBS, resuspended in DF/5%,
and further propagated on tissue-culture plastic.
Screening for gene expression using RT-PCR
PCR and RT-PCR analysis were used, respectively, to
screen the harvested mammary tumors and generated cell
lines for the presence and expression of the activated Neu
and TβRII-AS transgenes. Total RNA was isolated from fro-
zen tumors or 2.5 × 106 BRI-JM01, BRI-JM04, and BRI-
JM05 cells using Trizol (Invitrogen-Life Technologies,
Burlington, ON, Canada). PolyA+ RNA was obtained using
Oligotex resin (Qiagen, Mississauga, ON, USA), further
purified using DNAse I (NEN-Life Technologies, Boston,
MA, USA), and quantified using Ribogreen (MolecularBreast Cancer Research    Vol 6 No 5    Lenferink et al.
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Probes). First strand cDNA was synthesized in a final vol-
ume of 20 µl using 1 µg polyA+ RNA, an 18-base poly(dT)
primer, and 200 units Superscript II (Life Technologies). Of
this first strand reaction, 2 µl was used in a PCR reaction
using Neu or TβRII-AS specific primers under the condi-
tions described for screening of the transgenic mice.
Screening of the BRI-JM01 cell line for the presence of
TβRIII mRNA transcripts was carried out using two sets of
primers (set 1: 5'-CCT-CCT-CCA-CAG-ATT-TT-CCA-3'
and 5'-TGA-GTG-CTC-CCT-ATG-CTG-TG-3'; set 2: 5'-
ACG-ATC-CAT-GAC-AGT-GAC-CA-3' and 5'-GAA-GCT-
CAG-GAG-AAT-GGT-G-3'). For the RT-PCR reactions we
used glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as control (5'-ACC-ACA-GTC-CAT-GCC-ATC-
AC-3' and 5'-TCC-ACC-ACC-CTG-TTG-CTG-TA-3'). The
conditions used for both GAPDH and TβRIII PCR reactions
are similar to those described for the Neu amplification.
Plating efficiency, population doubling time, soft agar, 
and Matrigel assays
Plating efficiency of the three cell lines was determined by
seeding 40, 75, 150, 300, 600, and 1250 cells/well using
six-well plates. After 7 days the wells were rinsed with PBS,
the adherent colonies were stained with crystal violet
(0.2% weight/vol in 100% ethanol) for 5 min and rinsed
with water, and colonies visible were counted. The plating
efficiency was calculated as follows: (number of colonies/
number of cells seeded) × 100.
Population doubling time of the three cell lines was deter-
mined by seeding 1 × 105 cells/well using six-well plates.
Cells were trypsinized after 24, 48, 72 and 96 hours of cul-
turing and counted using a hemacytometer.
The anchorage-independent growth of the three cell lines
was studied by plating 105 cells in 0.3% agarose on top of
a layer of 0.6% agarose, both in DF/5%, using 100 mm
dishes. Cells were fed every week and colony growth was
evaluated by light microscopy after 7, 14, and 21 days of
culturing.
The ability of the BRI-JM01, BRI-JM04, and BRI-JM05 cell
lines to grow in three-dimensional culture was evaluated by
seeding 5 × 104 cells in growth factor reduced Matrigel
(Becton Dickinson) using 12-well plates. In addition to
these cells, we also seeded BRI-JM01 cells that had been
exposed to TGF-β1 for 48 hours and subsequently cultured
for more than five passages in the absence of this growth
factor. Cellular structures were evaluated 1, 2, and 3 weeks
after seeding by light microscopy and documented using a
Leitz Labovert (Leitz, Wetzlar, Germany) inverted
microscope.
Flow cytometry
The cell cycle distribution of the three cell lines was deter-
mined by flow cytometry. Briefly, exponentially growing
cells were trypsinized, washed and resuspended in ice-
cold PBS, and fixed in 70% ethanol (4°C). Cells were
washed the next day with ice-cold PBS, treated with 1 mg/
ml RNAse in PBS (15 min at 37°C), and stained (30 min at
room temperature) with propidium iodide (Molecular
Probes) to a final concentration of 50 µg/ml in PBS before
analysis. Cell populations were selected by forward and
side scattering using a 488 nm dichroic long pass filter,
and doublets were discriminated using the peak versus the
integrated signal of propidium iodide red fluorescence
(645 nm dichroic long pass and 620 nm band pass filter
set). Data were analyzed using Multicycle Software (Phoe-
nix Flow Systems, San Diego, CA, USA).
The epithelial character of the cell lines was evaluated by
cell surface E-cadherin expression. Cells were harvested
using nonenzymatic cell dissociation buffer (Sigma), then
washed twice with 10% FBS containing ice-cold PBS
(PBS/10%), and incubated (20 min at 4°C). Cells were pel-
leted, resuspended in PBS/10%, divided into three equal
portions, and incubated with an E-cadherin antibody
(1:1600), a control isotype equivalent antibody (anti-HA;
1:1600), or a secondary antibody Alexa-488 (1:400) in
PBS/10% (1 hour at 4°C). The cells were rinsed twice in
ice-cold PBS/10%, incubated with Alexa-488 secondary
antibody in the dark (1 hour at 4°C), washed twice with ice-
cold PBS/10%, and finally resuspended in 1 ml PBS. Via-
ble cell populations were selected using forward and side
scattering parameters with a 488 nm dichroic long pass fil-
ter. FITC or Alexa green fluorescent emission was detected
using a 550 nm dichroic long pass and 525 nm band pass
filter. Both cell cycle distribution and the cell surface E-cad-
herin expression of the three cell lines were analyzed using
a Coulter EPICS™ XL-MCL flow cytometer (Beckman-
Coulter, Fullerton, CA, USA) equipped with a 15 mW at
488 nm argon ion laser as the excitation source.
[3H]thymidine incorporation assays
Mv1Lu and BRI-JM01 cells (2 × 104 cells/well), and BRI-
JM04 and BRI-JM05 cells (4 × 104 cells/well) were seeded
in 24-well plates. The next day, cells were incubated for 4
hours in either serum-free (recombinant human EGF and
HRG-β1) or medium containing 1% FBS (TGF-β1), after
which serial dilutions of recombinant human EGF, HRG-β1
or TGF-β1 were added. After 24 hours, cells were pulse-
labeled for 3 hours by adding 0.5 µCi [3H]thymidine/well
(Amersham, Piscataway, NJ, USA). Cells were then rinsed
with PBS, trypsinized, and harvested using a cell harvester
(Cambridge Technology, Cambridge, MA, USA). [3H]thy-
midine incorporation was determined by scintillation count-
ing (Universol; ICN Biochemicals Inc.) using a β-counter
(LKB-Wallac, Turku, Finland).Available online http://breast-cancer-research.com/content/6/5/R514
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[125I]TGF-β cross-link affinity labeling studies
Mv1Lu and BRI-JM01 cells were seeded at a density of 1
× 105cells/well, and BRI-JM04 and BRI-JM05 cells at a
density of 2 × 105cells/well, using 12-well plates. The next
day, cells were cross-link affinity labeled with 100 pmol/l
[125I]TGF-β1 (NEN-Life Science Products) or [125I]TGF-β2
(iodination according to Philip and O'Connor-McCourt
[32]) in the absence or presence of 100× excess unla-
beled TGF-β1 in 300 µl binding buffer (D-PBS/Ca2+/Mg2+,
1 mg/ml BSA; pH7.4). Receptor bound ligand was cross-
linked using Bis(sulfosuccinimidyl) suberate (Pierce Bio-
technology, Rockford, IL, USA), as described previously
[33]. Cells were solubilized (1% Triton X100, 10% glyc-
erol, 1 mmol/l EDTA, 20 mmol/l Tris-HCl; pH 7.4) and equal
amounts of total protein were resolved on a linear 3–12%
gradient SDS-PAGE. Immunoprecipitations of the labeled
receptor complex were performed using antisera directed
against activin receptor-like kinase (ALK)-1, ALK-5 (Tβ RI)
or ALK-7 (antisera kindly provided by Dr P ten Dijke [34]),
TβRII and TβRIII, before SDS-PAGE. For treatment of the
cells with glycosaminoglycan-cleaving enzymes, subconflu-
ent monolayers were treated with 100 mU heparinitase I, II
and III, and 10 mU chondroitinase ABC (Ibex Technologies,
Montreal, PQ, USA) in 200 µl binding buffer (3 hours at
37°C) before cross-link affinity-labeling with 100 pmol/l
[125I]TGF-β1 or [125I]TGF-β2. Gels were fixed (1 hour, 10%
HAc/30% MeOH) at room temperature and dried, and
[125I]TGF-β cross-link affinity labeled proteins were imaged
using a PhosphorImager 401E and analyzed using Image-
Quant software (both purchased from Molecular Dynamics,
Sunnyvale, CA, USA).
Motility assays
Cell motility was determined using two independent
assays. For the wound closure assay, cells were seeded at
a density of 2 × 105 (BRI-JM01) and 4 × 105 (BRI-JM04
and BRI-JM05) cells/well in 12-well plates in DF/5% and
grown to confluency. Monolayers were then 'wounded' with
a pipet tip and the ability of the cells to migrate into this
'wound area' was monitored in the absence or presence of
100 pmol/l TGF-β1.
For the 'black ink assay', 24-well plates were coated with
ink according to Al-Moustafa and coworkers [35], with
modifications. Briefly, 24-well plates were coated with
0.1% gelatin (30 min at 37°C). Excess gelatin was aspired
from the wells, and a black ink solution (Demco, St.-Lam-
bert, PQ, Canada; 1:3 dilution in sterile ddH2O) was
added, covering the bottom of the wells. After 5 min, the
excess ink was removed and the wells were rinsed vigor-
ously with sterile ddH2O and finally PBS. Cells were
seeded immediately after the ink-coated wells were pre-
pared at a density of 2 × 104 cells/well in DF/5% in the
absence or presence of 100 pmol/l TGF-β1.
Cell motility in both assays was determined 24 hours after
TGF-β addition using a Leitz Labovert inverted microscope.
The ink particle-free tracks, produced by the migrating cells
in the black ink assay, of five microscopic fields were quan-
tified using ImageJ freeware http://rsb.info.nih.gov/ij/. Dif-
ferences in endogenous and TGF-β1  induced motility
between the three cell lines was expressed as the relative
fold/cell per 24 hours using the least motile BRI-JM05 cell
line as a standard.
Immunofluorescence microscopy
BRI-JM01 cells were seeded in glass chamber slides (Lab-
Tek, NalgeNunc International, Rochester, NY, USA) at a
density of 1 × 104 cells/0.8 cm2 in DF/5%. A total of 100
pmol/l TGF-β1 was added and the cells were incubated for
a n  a d d i t i o n a l  2 4  h o u r s .  C e l l s  w e r e  r i n s e d  w i t h  P B S
(repeated after each of the following steps), fixed in ice-
cold 100% methanol (10 min), and permeabilized with
0.1% Triton X100 in PBS (5 min at room temperature).
Nonspecific sites were blocked (30 min at room tempera-
ture) with 1.5% nonfat milk-powder in PBS (PBS/1.5%
milk), followed by an incubation with antibodies raised
against ZO-1 (1/500), E-cadherin (1/500), β-catenin (1/
1000), N-cadherin (1/1000), and vimentin (1/50), all in
PBS/1.5% milk. This was followed by incubation with a flu-
orescently conjugated secondary antibody (1/500 in PBS/
1.5% milk) for 1 hour at room temperature. F-actin filaments
were stained, after fixation of the cells in 4% paraformalde-
hyde, with Texas-red conjugated phalloidin (30 min at room
temperature). Nuclei were counter stained on all slides (5
min at room temperature) using 0.4 µg/ml 4,6-diamidino-2-
phenylindole (Sigma) in PBS. Slides were mounted using
antifade (Molecular Probes) and fluorescent images were
captured using a cooled Coolsnap CCD digital camera
mounted on a Leitz upright microscope.
Immunoprecipitations and western blot analysis
Semiconfluent monolayers of BRI-JM01, BRI-JM04, and
BRI-JM05 cells were rinsed with PBS before lysis in CSK
buffer (150 mmol/l NaCl, 10 mmol/l Pipes, 30 µmol/l
MgCl2, 300 mmol/l sucrose, 2% Triton X-100) supple-
mented with a protease inhibitor cocktail (Roche Diagnos-
tics, Laval, PQ, USA). The total ErbB-1, ErbB-2, ErbB-3,
and ErbB-4 content of the cell lines was determined by
resolving 20 µg total protein by 7.5% SDS-PAGE followed
by western blotting. The phosphorylation status of the
ErbB-2/Neu receptor was determined by immunoprecipta-
tion of ErbB-2/Neu, followed by western blotting with a
phosphotyrosine specific antibody. Briefly, semiconfluent
monolayers of BRI-JM01, BRI-JM03, and BRI-JM04 cell
lines were lysed in lysis buffer (150 mmol/l NaCl; 50 mmol/
l Tris-HCl, pH 8.0; 0.55% NP-40; 50 mmol/l NaF). Total
protein (500 µg) was precleared with protein G sepharose
(4 hours at 4°C) and the ErbB-2/Neu receptor was precip-
itated (16 hours at 4°C) using 2 µg monoclonal ErbB-2/Breast Cancer Research    Vol 6 No 5    Lenferink et al.
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Neu antibodies coupled to protein G sepharose. The next
day precipitates were rinsed five times with lysis buffer and
resolved by 7.5% SDS-PAGE.
The E-cadherin, N-cadherin, and β-catenin content of the
BRI-JM01 cells was determined by lysing BRI-JM01 cells in
CSK buffer after 24, 72, and 120 hours of TGF-β1 treat-
ment (100 pmol/l final concentration) and resolving 20 µg
total protein by 10% SDS-PAGE followed by western
blotting.
All proteins were transferred to nitrocellulose, nonspecific
sites were blocked using 5% non-fat milk powder in TBS
(20 mmol/l Tris-HCl, pH 7.6; 137 mmol/l NaCl) containing
0.1% Tween 20 (TBS-T) for 1 hour at room temperature,
and filters were then incubated with primary antibody (E-
cadherin, ErbB-1, ErbB-2, ErbB-3, and ErbB-4, 1:500; N-
cadherin and β-catenin, 1:1000; phospho-tyrosine, 1 µg/
ml) in TBS-T/5% nonfat milk (16 hours at 4°C). Filters were
washed with TBS-T (3 × 10 min), incubated with the appro-
priate secondary HRP-conjugated antibody (1:10,000, 1
hour at room temperature) in TBS-T/5% nonfat milk, and
washed with TBS-T (3 × 10 min). Immunoreactive bands
were visualized by chemiluminescence (Perkin Elmer, Bos-
ton, MA, USA).
Results
Activated Neu and TβRII-AS transgene expression in 
mammary tumors and derived cell lines
To provide mammary epithelial cell lines that may exhibit a
combination of reduced TGF-β signaling due to TβRII-AS
expression, and activated oncogenic pathways due to Neu
expression, we isolated two cell lines (named BRI-JM01
and BRI-JM05) from tumors from the bigenic MMTV/acti-
vated Neu + TβRII-AS mice that we have generated. As a
potential control, we also isolated a cell line (termed BRI-
JM04) from a tumor taken from an MMTV/activated Neu
expressing animal. Our analysis of transgene expression at
the level of the tumors using RT-PCR analysis of polyA+
RNA showed that all of the tumors from four bigenic
MMTV/activated Neu + TβRII-AS mice expressed both the
Neu and TβRII-AS transgenes (Fig. 1a, left panel). Addition-
ally, as expected (Muller WJ, personal communication), RT-
PCR analysis indicated that all the mammary tumors iso-
lated from MMTV/activated Neu transgenic animals
expressed the Neu transgene (Fig. 1a, right panel). In con-
trol experiments conducted in the absence of reverse tran-
scriptase, no PCR products were generated for any of the
transgenes (data not shown), indicating that the polyA+
RNA was free of genomic DNA contamination.
In contrast to the results obtained with the tumor samples,
RT-PCR analysis of the BRI-JM01 and BRI-JM05 cell lines
(which were established from MMTV/activated Neu +
TβRII-AS bigenic tumors) unexpectedly indicated that the
TβRII-AS transgene was not expressed (Fig. 1b, left panel).
The BRI-JM04 cell line (from an MMTV/activated Neu mam-
mary tumor) did not contain the TβRII-AS message, as
expected. PCR analysis, using genomic DNA isolated from
the three cell lines, showed that the lack of TβRII-AS
expression in the BRI-JM01 cells was due to the loss of the
TβRII-AS sequence from the genome (Fig. 1c, middle
panel). In contrast, the PCR analysis showed that BRI-
JM05 genomic DNA contained the TβRII-AS sequence,
implying that some form of gene silencing was responsible
for the loss of TβRII-AS expression in this cell line (Fig. 1c,
middle panel). With respect to Neu transgene expression,
RT-PCR and PCR analysis showed that all three cell lines
carried the Neu oncogene sequence in their genomes (Fig.
1c, right panel); however, only the BRI-JM04 and BRI-JM05
cells expressed the Neu transgene (Fig. 1b, right panel).
The results of these PCR and RT-PCR analyses are sum-
marized in Table 1 and indicate that these cell lines will not
serve as good models for studying the effect of TβRII-AS
expression on TGF-β signaling because the expression of
the TβRII-AS transgene was not maintained. However, the
results do suggest that these lines may be useful for stud-
ying TGF-β signaling in the absence (BRI-JM01) versus
presence (BRI-JM04 and BRI-JM05) of activated Neu
oncogene signaling.
Confirmation of epithelial character and 
characterization of in vitro growth
The procedures that were used to establish these new cell
lines favor the isolation of epithelial cells. However, using
light microscopy, we observed that only the BRI-JM01 cells
exhibited the typical epithelial-like polygonal morphology
(Fig. 2a). Flow cytometry (Fig. 2b), using an anti-E-cadherin
antibody and nonpermeabilized cells, revealed that more
than 95% of the cells in the three cell lines expressed cell
surface E-cadherin, confirming their epithelial character.
Next, we determined the doubling time and the plating effi-
ciency of the three mammary tumor cell lines. The BRI-
JM01 cell line exhibited the shortest doubling time (14
hours) and a relatively high plating efficiency (78%). BRI-
JM04 and BRI-JM05 cells were shown to have much longer
doubling times (22 and 25 hours, respectively) and lower
plating efficiencies (55% and 41%, respectively). Using
flow cytometry, we determined the cell cycle distribution of
exponentially growing BRI-JM01, BRI-JM04, and BRI-JM05
cells. The S+G2/M ratio confirmed that the BRI-JM01 cell
line contained the most rapidly growing cell population,
whereas the BRI-JM04 and BRI-JM05 populations multi-
plied more slowly (Table 2), which is consistent with the
doubling time results. It is interesting that the one cell line
that did not maintain expression of the activated Neu onco-
gene exhibited the fastest growth rate.Available online http://breast-cancer-research.com/content/6/5/R514
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Culturing the three cell lines for several passages in phenol
red-free modified Eagle's medium containing 10% char-
coal-stripped/dextran-treated  bovine serum did not alter
their growth characteristics, indicating that these cells are
able to grow in the absence of steroid hormones.
Anchorage independent growth of the cells in soft agar,
and growth of the cells in three-dimensional culture
(Matrigel) was assessed. Only the BRI-JM05 cells were
capable of forming colonies in soft agar; however, the
clonogenic capacity of this cell line was under 5% (data not
Figure 1
Evaluation of the activated Neu and transforming growth factor-β type II receptor antisense RNA (TβRII-AS) gene expression in mouse mammary  tumor virus (MMTV) transgenic mouse mammary tumors and the derived cell lines Evaluation of the activated Neu and transforming growth factor-β type II receptor antisense RNA (TβRII-AS) gene expression in mouse mammary 
tumor virus (MMTV) transgenic mouse mammary tumors and the derived cell lines. (a) Activated Neu and TβRII-AS transgene expression was deter-
mined by RT-PCR in four independent MMTV/activated Neu + TβRII-AS mammary tumors (left panel), in one MMTV/activated Neu mammary tumor 
(right panel), and (b) the BRI-JM01, BRI-JM04 and BRI-JM05 cell lines. First strand reactions were carried out in the presence or absence of reverse 
transcriptase (± RT). (c) Genomic DNA obtained from the BRI-JM01, BRI-JM04, and BRI-JM05 cell lines was evaluated by PCR for the presence of 
the TβRII-AS (middle) and activated Neu (right) transgenes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as positive control 
(parts a and c, left panels).Breast Cancer Research    Vol 6 No 5    Lenferink et al.
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shown). Both the BRI-JM04 and BRI-JM05 cell lines prolif-
erated relatively rapidly in Matrigel and formed structures
approximately 50–100 µm in diameter within 2 weeks after
seeding the cells (Fig. 2c). The BRI-JM01 cell line also
formed structures but at a slower rate, with structures of
approximately 25–50 µm in diameter being detected after
2 weeks of culturing.
Response to growth factors and receptor analysis
We demonstrated that the BRI-JM04 and BRI-JM05, but
not the BRI-JM01, cells express the message for the acti-
vated Neu oncogene (Fig. 1b). Next, we wished to deter-
mine the growth response of the three cell lines to EGF and
HRG-β1 by measuring [3H]thymidine incorporation, and to
correlate this response with the levels of expression of the
ErbB-1, ErbB-3 and ErbB-4 receptors, in addition to that of
the activated Neu receptor. The BRI-JM01 and BRI-JM04,
but not the BRI-JM05 cells, were growth stimulated by
recombinant human EGF (Fig. 3a), whereas only the BRI-
JM01 cells were significantly stimulated by HRG-β1 (Fig.
3b). Western blot analysis (Fig. 3c) showed that the BRI-
JM01 and BRI-JM04 cells expressed significant levels of
ErbB-1, whereas the BRI-JM05 cells expressed much
lower levels of ErbB-1. Western blot analysis also showed
that the BRI-JM04 and BRI-JM05 cells expressed high lev-
els of the activated Neu protein (Fig. 3c), confirming the
RT-PCR data (Fig. 1b). In addition, immunoprecipitation of
the ErbB-2/Neu receptor followed by western blot analysis
using an anti-phosphotyrosine antibody showed that the
receptor was highly phosphorylated in the activated Neu
expressing BRI-JM04 and BRI-JM05 cell lines (Fig. 3c).
Finally, all three cell lines expressed relatively high levels of
ErbB-3 and ErbB-4 receptors. The correlation between
ErbB-1, ErbB-2, ErbB-3, and ErbB-4 receptor expression
and recombinant human EGF and HRG-β1 responsiveness
is discussed in terms of receptor expression and het-
erodimer formation below.
Treatment with TGF-β1 in the presence of serum resulted in
growth inhibition of all three cell lines (Fig. 3d), as might be
expected of cells of epithelial origin. Cross-link affinity labe-
ling of cell surface TGF-β receptors using [125I]TGF-β1
revealed the presence of two receptors with molecular
weights of 53 kDa and 70 kDa on the three cell lines (Fig.
3e, upper panel), whereas a third receptor (molecular
weight approximately 250 kDa) could be detected on only
the BRI-JM04 and BRI-JM05 cells. These molecular
weights are characteristic of type I, II, and III TGF-β recep-
tors. The identity of the type II and III TGF-β receptors was
confirmed by immunoprecipitation of the [125I]TGF-β1
cross-link affinity labeled receptors, using specific antibod-
ies (data not shown). In the case of type I TGF-β receptors,
it is known that TGF-β most often interacts with and acti-
vates the Alk-5 type I receptor. However, it is also capable
of interacting with and activating another type I receptor,
termed Alk-1 [36]. In all three cell lines, using specific anti-
bodies, we determined that the affinity labeled 53 kDa
receptor corresponded to Alk-5 and not Alk-1.
The type III receptor is known to contain heparin and chon-
droitin sulfate glycosaminoglycan chains, which results in it
exhibiting a diffuse migration pattern on SDS-PAGE. In
order to collapse the type III receptor into a tighter band
and thereby enhance our ability to detect it at the cell sur-
face, we treated the three cell lines with heparinitase I, II
and III, and chondroitinase ABC before cross-link affinity
labeling with [125I]TGF-β1 or [125I]TGF-β2 (Fig. 3e, bottom
panels). Although, as expected, this deglycosylation proce-
dure collapsed the TβRIII receptor band into a labeled core
protein of approximately 115 kDa on the BRI-JM04 and
BRI-JM05 cells, it did not reveal the presence of the TβRIII
receptor on the BRI-JM01 cells. However, RT-PCR analysis
(using two independent sets of TβRIII specific primers) indi-
cated that these cells express the TβRIII message (Fig. 3f).
These results indicate that either the TβRIII message is not
translated efficiently or that trafficking of the TβRIII to the
cell surface is impaired in these cells.
Table 3 summarizes the ErbB receptor and TGF-β receptor
expression patterns in the three cell lines, and Table 4 gives
an overview of their responsiveness to TGF-β1, recom-
binant human EGF and HRG-β1.
Cell motility assays
TGF-β is known to stimulate motility in several epithelial cell
lines, including the NMuMG and EpH4 mammary epithelial
Table 1
PCR (genomic) and RT-PCR (message) analysis for the presence of Neu and TβRII-AS in the BRI-JM01, BRI-JM04 and BRI-JM05 cell 
lines
BRI-JM01 BRI-JM04 BRI-JM05
Activated Neu (genomic) + + +
Activated Neu (message) - + +
TβRII-AS (genomic) - - +
TβRII-AS (message) - - -
TβRII-AS, transforming growth factor-β type II receptor antisense RNAAvailable online http://breast-cancer-research.com/content/6/5/R514
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Figure 2
Evaluation of the morphologic character of the BRI-JM01, BRI-JM04, and BRI-JM05 cell lines Evaluation of the morphologic character of the BRI-JM01, BRI-JM04, and BRI-JM05 cell lines. (a) Phase contrast microscopy revealed the typical 
epithelial 'cobble-stone'-like morphology for the BRI-JM01 cell line, as compared with the morphology of the BRI-JM04 and BRI-JM05 cell lines. (b) 
Flow cytometry revealed that the cell populations of all three cell populations are more than 95% positive for the junctional epithelial marker E-cad-
herin. Cells labeled with either an irrelevant primary isotype equivalent antibody (HA) or the secondary antibody alone (Alexa-488) served as negative 
controls (top and middle panel, respectively). (c) BRI-JM04 and BRI-JM05 cells seeded in Matrigel grew within 2 weeks, whereas BRI-JM01 cells 
grew at a slower rate.Breast Cancer Research    Vol 6 No 5    Lenferink et al.
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cell lines. We therefore assessed the endogenous, and
TGF-β1-induced, motility of the three cell lines that we have
isolated using two independent assays. In the first assay,
confluent monolayers of cells were 'wounded' with a pipet
tip, and the movement of the cells into the wound area was
monitored in the absence or presence of 100 pmol/l TGF-
β1. Figure 4a shows that BRI-JM01 cells exhibited a TGF-
β1-induced increase in motility. This 'wound healing' effect
was not due to an increase in cell proliferation because we
demonstrated that these cells were clearly growth inhibited
by 100 pmol/l TGF-β1 (Fig. 3d). In contrast, TGF-β1 did not
affect the motility of the BRI-JM04 and BRI-JM05 cell lines
in the wound assay.
The second assay is a 'black ink assay' in which the cells
were sparsely seeded on an ink-coated surface and then
monitored for cell movement, which appears as ink particle
cleared tracks on the plastic. This motility assay confirmed
the results of the wound assay (i.e. the presence of TGF-β1
significantly increased the motility of the BRI-JM01 cells,
but not of the BRI-JM04 and BRI-JM05 cells; Fig. 4b).
Quantification of these particle-free tracks using ImageJ
software showed that the basal motility of the BRI-JM01
and BRI-JM04 cells was approximately twice that of the
BRI-JM05 cells, and that TGF-β1 stimulated the motility of
the BRI-JM01 cells approximately 1.7-fold (Fig. 4c).
Evaluation of TGF-β1 induced epithelial-to-
mesenchymal transition of BRI-JM01 cells
Using phase contrast microscopy, we also observed that,
in addition to having their growth inhibited and their motility
stimulated by TGF-β1, BRI-JM01 cells exhibited a striking
morphologic change in response to this growth factor,
either in the presence (Fig. 5a) or in the absence (data not
shown) of serum. The appearance of the cells changed
from a homogeneous epithelial-like cuboidal morphology to
a spindle-shaped morphology (Fig. 5a, phase contrast).
We therefore investigated whether these cells were under-
going an EMT similar to that described for the NMuMG and
Ras-transformed EpH4 cells [22,23] by evaluating the
expression and/or relocalization of several epithelial and
mesenchymal markers.
Using immunofluorescence microscopy, we observed that
the BRI-JM01 cells were indeed undergoing an EMT-like
process, which was characterized by the following: relocal-
ization of the cell adhesion proteins E-cadherin, N-cadherin,
and β-catenin; loss of the tight junctional protein ZO-1;
acquisition of actin stress fibers; and reorganization of the
cytoskeletal intermediate filament protein vimentin (Fig. 5a).
Flow cytometric analysis, using an anti-E-cadherin antibody
and nonpermeabilized cells, confirmed that TGF-β1 expo-
sure caused a relocalization of E-cadherin. Cell surface E-
cadherin expression decreased approximately 50% after
48 hours, and almost 100% after 120 hours of TGF-β1
treatment (Fig. 5b). Immunoblot analysis of whole cell
lysates showed that the effect on E-cadherin was primarily
one of relocalization because the total E-cadherin content
of BRI-JM01 cells was only slightly diminished over the
TGF-β1 time course (Fig. 5c). A similar phenomenon was
observed for N-cadherin and β-catenin (i.e. both proteins
translocate from the cell surface to cytosolic compartments
upon TGF-β1  exposure [Fig. 5a], with no significant
decrease in total protein [Fig. 5c]).
There is an ongoing discussion in the literature as to what
criteria may be used to define an EMT in vitro and to distin-
guish the EMT phenotype from a 'scattering' phenotype
[23]. Both phenotypes exhibit disruption of cell junctions,
fibroblastoid morphology, and enhanced motility. However,
it has been suggested that they can be distinguished by
reversibility studies with the EMT phenotype, but not the
scattering phenotype, persisting after withdrawal of the
stimulus [23]. We investigated the reversibility of the EMT
phenotype in the BRI-JM01 cells by treating cells with TGF-
β1 for 48 hours and then culturing them for at least five pas-
sages in the absence of TGF-β1. In two-dimensional culture
on plastic, these cells maintained their mesenchymal mor-
phology (data not shown). When grown for 3 weeks in
three-dimensional culture in Matrigel, the TGF-β1 'primed'
cells formed larger structures than did the nontreated BRI-
JM01 cells (Fig. 5d). Together, these results indicate that,
in the BRI-JM01 cells, EMT is maintained as a metastable
phenotype that is independent of TGF-β1 stimulation.
Table 2
Flow cytometry analysis of the cell cycle distribution of BRI-JM01, BRI-JM04, and BRI-JM05 using propidium iodide
Percentage in cell cycle phase
G1 SG 2/M
NS0 49.9 14.3 20.9
BRI-JM01 51.6 26.1 22.3
BRI-JM04 62.9 21.0 16.1
BRI-JM05 71.1 13.5 11.4
Murine NS0 cells were used as control.Available online http://breast-cancer-research.com/content/6/5/R514
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Discussion
The present study describes the characterization of three
new mouse epithelial cell lines (BRI-JM01, BRI-JM04, and
BRI-JM05) derived from mammary tumors arising in MMTV/
activated Neu or MMTV/activated Neu + TβRII-AS trans-
genic animals. Although all tumor samples were shown to
express the expected transgene(s) by RT-PCR (i.e. acti-
vated Neu or activated Neu + TβRII-AS), the derived cell
lines failed to express one or both of the transgenes. Both
of the cell lines that were established from MMTV/activated
Neu + TβRII-AS bigenic tumors (the BRI-JM01 and BRI-
JM05 cells) did not express the TβRII-AS transgene. The
lack of expression of the TβRII-AS transgene in the BRI-
JM01 cells was due to deletion of the transgene from the
genome, whereas in the BRI-JM05 cells the gene was
present in genomic DNA but was not expressed. With
respect to Neu transgene expression, all three cell lines
carried the Neu oncogene sequence in their genomes, but
only the BRI-JM04 and BRI-JM05 cells expressed the Neu
transgene message and the constitutively phosphoryated
ErbB-2/Neu protein.
We examined the general morphology and growth charac-
teristics of the three cell lines and observed that the BRI-
JM01 cells exhibited a very short doubling time and high
plating efficiency, as compared with the BRI-JM04 and
BRI-JM05 cells. This result is somewhat surprising consid-
ering that the BRI-JM01 cells are the one cell line that does
not express the Neu oncogene. Despite the expression of
the cell adhesion protein E-cadherin by all three lines, only
Figure 3
Growth response of the three cell lines to recombinant human epidermal growth factor (hEGF), heregulin (HRG)-β1, and transforming growth factor  (TGF)-β1 Growth response of the three cell lines to recombinant human epidermal growth factor (hEGF), heregulin (HRG)-β1, and transforming growth factor 
(TGF)-β1. [3H]thymidine incorporation measured in BRI-JM01, BRI-JM04, and BRI-JM05 cell lines after 24 hours of exposure to serial dilutions of (a) 
hEGF, (b) HRG-β1, or (d) TGF-β1. Experiments were conducted in quadruplicate and repeated three times with similar results (for details see text). 
(c) Western blot analysis of whole cell lysates (20 µg total protein/lane) evaluating ErbB-1, ErbB-2, ErbB-3, and ErbB-4 expression. Additional ErbB-
2/Neu immunoprecipitations showed this receptor to be highly phosphorylated in the BRI-JM04 and BRI-JM05 cells. (e) Affinity cross-link labeling of 
the TGF-β type I, II, III receptors expressed on the BRI-JM01, BRI-JM04 and BRI-JM05 cells using [125I]TGF-β1 in the absence (-) or presence (+) of 
100× excess of unlabeled TGF-β1. Enzymatic deglycosylation using both heparinitase I/II/III and chondroitinase ABC collapses the diffusely migrat-
ing TGF-β type III receptor band to a core protein (approximately 115 kDa, indicated as TβRIII**) labeled with either [125I]TGF-β1 or [125I]TGF-β2. 
TGF-β responsive Mv1Lu cells served as a positive control in the TGF-β growth assay and the cell surface cross-link affinity labeling studies. (f) RT-
PCR analysis of BRI-JM01 mRNA using two different primer sets (set 1, set 2) confirmed the presence of TGF-β type III receptor transcripts in the 
BRI-JM01 cells. TGF-β type III receptor-expressing BRI-JM05 cells (part e) were used as a positive control for TGF-β type III receptor expression, 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard. Experiments were repeated twice with similar results.Breast Cancer Research    Vol 6 No 5    Lenferink et al.
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the BRI-JM01 cells exhibited a typical 'cobble-stone' epi-
thelial morphology. The lack of a typical epithelial morphol-
ogy by the BRI-JM04 and BRI-JM05 cells may be due to
their high level of Neu expression.
In addition to determining the level of expression of the
Neu/erbB-2 transgene protein in the three cell lines, we
also examined the level of expression of the ErbB-1, ErbB-
3 and ErbB-4 receptors, and correlated the ErbB receptor
expression patterns with the growth responses to EGF and
HRG-β1. EGF is the primary ligand for the ErbB-1 receptor,
whereas HRG-β1 binds and activates ErbB-3 and, to a
lesser extent, ErbB-4 [37]. We found that the BRI-JM01
cells were growth stimulated by both recombinant human
EGF and HRG-β1, whereas the BRI-JM04 cells were stim-
ulated only by recombinant human EGF. In contrast, the
BRI-JM05 cells were rather insensitive to both recombinant
human EGF and HRG-β1. Immunoblot analysis showed
that the BRI-JM01 cells expressed significant levels of
ErbB-1, ErbB-3 and ErbB-4 receptors; that BRI-JM04 cells
expressed high levels of ErbB-1, ErbB-2, ErbB-3 and ErbB-
4 receptors; and that BRI-JM05 cells expressed high levels
of ErbB-2, ErbB-3 and ErbB-4 receptors. The relatively
high level of ErbB-1 receptors in the BRI-JM01 and BRI-
JM04 cells probably accounts for their responsiveness to
recombinant human EGF as compared with the BRI-JM05
cells. The presence of ErbB-1 and ErbB-3 receptors in the
BRI-JM01 cells should enable the formation of ErbB-1/
ErbB-3 heterodimers, thereby accounting for the respon-
siveness of these cells to HRG-β1. The relative insensitivity
of the BRI-JM04 and BRI-JM05 cells, which also express
the ErbB-1 and ErbB-3 receptors, to HRG-β1 may be
explained by the fact that these cells express high levels of
activated Neu, which is capable of dimerization with ErbB-
3 in a ligand independent manner. Accordingly, it may
sequester the ErbB-3 receptor and therefore prevent it
from heterodimerizing with ErbB-1 in response to HRG-β1.
We also determined for the three cell lines the level of
expression of the TGF-β type I, II and III receptors, and their
growth and motility responses to TGF-β. The BRI-JM04
and BRI-JM05 cells expressed similar levels of the TGF-β
type I, II and III receptors, whereas the BRI-JM01 cells
expressed similar levels of the TGF-β type I and II receptors
but no detectable type III receptor. All three cell lines were
growth inhibited by TGF-β1. This is not unexpected for
breast epithelial cells, which express the type I and II recep-
tors, and indicates that the downstream signaling compo-
nents that are critical for the growth inhibitory response
have not been inactivated in these cell lines. With respect
to their response in the two motility assays, the presence of
TGF-β1 significantly increased the motility of the BRI-JM01
cells, but not the BRI-JM04 and BRI-JM05 cells.
Several lines of evidence in mouse models and humans
indicate that TGF-β signaling promotes late stage tumor
progression/metastasis in spite of its tumor suppressor
effects in early tumorigenesis, and that this tumor promoter
effect correlates with its ability to promote an EMT in tumor
epithelial cells [23,38]. Most current studies examining the
molecular mechanisms that underlie the EMT process are
performed in vitro with cultured epithelial cell lines that con-
vert to a fibroblast-like morphology under specific condi-
tions. In the case of breast epithelial cell lines, most do not
respond to TGF-β with a recognizable EMT response. This
may be due to the fact that culture conditions do not always
maintain cell polarity and/or facilitate motility. In combina-
tion with this, the gene expression program of individual cell
Table 3
Overview of the ErbB and TGF-β receptor expression profiles of the BRI-JM01, BRI-JM04 and BRI-JM05 cells
ErbB-1 ErbB-2/
activated Neu
ErbB-3 ErbB-4 TβRI TβRII TβRIII
BRI-JM01 ++ + +++ +++ ++ ++ ±
BRI-JM04 ++ +++ +++ +++ ++ ++ ++
BRI-JM05 + +++ +++ +++ ++ ++ ++
TβRI/TβRII/TβRIII, transforming growth factor-β type I/II/III receptor; TGF, transforming growth factor.
Table 4
Summary of the response to hEGF, HRG-β1, and TGF-β1 by BRI-JM01, BRI-JM04, and BRI-JM05 cells
HEGF HRG-β1 TGF-β1
BRI-JM01 +++ +++ ++
BRI-JM04 +++ ± ++
BRI-JM05 ± ± ++
hEGF, recombinant human epidermal growth factor; HRG, heregulin; TGF, transforming growth factor.Available online http://breast-cancer-research.com/content/6/5/R514
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Figure 4
Transforming growth factor (TGF)-β1 induces increased motility in the BRI-JM01 cell line Transforming growth factor (TGF)-β1 induces increased motility in the BRI-JM01 cell line. Endogenous (CTL) and TGF-β1-induced motility of the BRI-
JM01, BRI-JM04, and BRI-JM05 cells was determined in a (a) wound-closure assay and a (b) black ink-assay (see text for details). Each experiment 
was repeated at least twice, with similar results. (c) Particle-free tracks were quantitated (using ImageJ freeware) and expressed as the relative fold 
ink clearance (± standard error of the mean) of the least motile BRI-JM05 cell line 24 hours after seeding the three cell line in the absence (white 
bars) or presence of 100 pmol/l TGF-β1 (black bars). BRI-JM01 and BRI-JM04 cells are approximately twice as motile as the BRI-JM05 cells; how-
ever, TGF-β1 only stimulates the motility of the BRI-JM01 cells (for details see text).Breast Cancer Research    Vol 6 No 5    Lenferink et al.
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lines may be such that intrinsic inhibitory mechanisms are
expressed, or that downstream mediators are not
expressed. Having observed that TGF-β1  significantly
increased the motility of the BRI-JM01 cells, we
investigated this cell line further to determine whether it
was responding to TGF-β with an EMT response similar to
that described for the NMuMG and Ras-transformed EpH4
breast epithelial cell lines.
Currently, the criteria for defining an EMT in vitro has varied
in different studies, but it is generally accepted that it
involves, in addition to an increase in cell motility, the
acquisition of a mesenchymal morphology and mesenchy-
mal markers, the dissolution of epithelial cell–cell contacts,
and a remodeling of the cytoskeleton. Additionally, it has
been suggested that a true EMT phenotype is metastable
(i.e. eventually it becomes independent of exogenous
stimuli) [23]. We observed that the BRI-JM01 cells exhib-
ited a rapid and synchronous morphologic response to
TGF-β1, with the cells exhibiting a homogeneous epithelial-
like cuboidal morphology before treatment and a relatively
homogeneous spindle-shaped morphology after treatment.
Figure 5
Transforming growth factor (TGF)-β1 induces an epithelial-to-mesenchymal transition (EMT) in the BRI-JM01 cell line Transforming growth factor (TGF)-β1 induces an epithelial-to-mesenchymal transition (EMT) in the BRI-JM01 cell line. (a) Immunofluorescence 
microscopy demonstrating the altered localization of E-cadherin, N-cadherin and β-catenin, the rearrangement of F-actin and vimentin filaments, and 
the disappearance of ZO-1 that accompany the TGF-β1 induced EMT (see text for details). (b) Flow cytometry of nonfixed live cells monitoring the 
presence of E-cadherin at the cell surface of BRI-JM01 cells that were exposed to TGF-β1 for up to 120 hours. Nonspecific isogenic IgG (HA) and 
cells grown in the absence of TGF-β1 (CTL) were used as a negative and positive control, respectively. (c) Western blot analysis determining the 
total cellular content of E-cadherin, N-cadherin and β-catenin in BRI-JM01 cells cultured for 24, 72 and 120 hours in the absence (CTL) or presence 
of TGF-β1 (see text for details). (d) BRI-JM01 cells were treated with TGF-β1 for 48 hours (BRI-JM01T) and passaged several times in the absence 
of this growth factor. When seeded in Matrigel these 'TGF-β1 primed' BRI-JM01 cells formed larger three-dimensional structures than did the non-
treated cells.Available online http://breast-cancer-research.com/content/6/5/R514
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With respect to the dissolution of epithelial cell–cell con-
tacts, using immunofluorescence microscopy we found
that the cell adhesion proteins E-cadherin, N-cadherin, and
β-catenin were relocalized away from the cell surface, and
that the total amount of the tight junctional protein ZO-1
significantly decreased after TGF-β treatment.
The cytoskeletal intermediate filament protein vimentin, a
mesenchymal marker, was expressed before treatment, but
it was reorganized into filamentous structures upon treat-
ment. The presence of vimentin in the untreated cells,
which have a clear epithelial morphology, may not be sur-
prising because its transcription is very sensitive to serum
factors [37], rendering its presence per se an unreliable
marker of mesenchymal cells.
In reversibility studies, we found that the mesenchymal mor-
phology of the BRI-JM01 cells was maintained in two-
dimensional culture for several passages after removal of
TGF-β1. Additionally, differences in growth in three-dimen-
sional Matrigel cultures could be observed 3 weeks after
seeding the TGF-β1 'primed' cells in Matrigel. Because
reversibility may be a feature that distinguishes a 'scatter-
ing' phenotype from an EMT phenotype, we suggest that
the BRI-JM01 cells may be regarded as undergoing a rela-
tively complete EMT process.
It is of interest to examine the characteristics that the BRI-
JM01, NmuMG, and Ras-transformed EpH4 cell lines have
in common in order to gain insight into what may predis-
pose these breast epithelial cell lines to undergo an EMT in
response to TGF-β. A distinguishing feature of the BRI-
JM01 cells, at least as compared with the BRI-JM04 and
BRI-JM05 cells, is their apparent lack of expression of the
type III TGF-β receptor. It is unlikely that this accounts for
their ability to exhibit an EMT response to TGF-β, however,
because NMuMG cells express this receptor at a signifi-
cant level (data not shown). Another distinguishing feature
of the BRI-JM01 cells is their lack of expression of the acti-
vated Neu oncogene, even though they were isolated from
tumors expressing this oncogene. Because both the
NMuMG and EpH4 lines are nontransformed mouse mam-
mary epithelial cell lines, a lack of oncogene expression
may be a characteristic that they share with the BRI-JM01
cells. However, in the case of the EpH4 cells, the EMT
response to TGF-β requires the expression of Ras variants
that induce hyperactivation of the extracellular signal-regu-
lated kinase/MAPK pathway [22,23]. We have found that
the TGF-β-induced EMT response of the BRI-JM01 cells is
not inhibited by the farnesyltransferase inhibitor L-744832
(data not shown), suggesting that the EMT response of
these cells does not depend on the presence of activated
Ras.
Based on the preceding discussion, it would appear that
the cell line that the BRI-JM01 cells most resemble in terms
of their TGF-β-induced EMT response is the NMuMG cell
line. However, in that cell line, the ALK-1 TGF-β type I
receptor was implicated as mediating the TGF-β-induced
EMT [14]. In the BRI-JM01 cells, we found that the proto-
typic TGF-β type I receptor ALK-5 is expressed, whereas
ALK-1 is not. This indicates that a TGF-β-induced EMT can
be mediated either by ALK-1 or ALK-5, depending upon the
cell context.
One other unusual characteristic of the BRI-JM01 cells is
that they express N-cadherin in addition to E-cadherin. Var-
ious studies have shown that E-cadherin is involved in
maintenance of the normal phenotype of epithelial cells
[39]. In contrast, it has been demonstrated that expression
of another member of the cadherin family, namely N-cad-
herin, actually may contribute to an invasive phenotype. For
example, it was shown that expression of N-cadherin in BT-
20 and MCF7 human breast epithelial cell lines increased
cell motility and invasion [40,41]. Additionally, based on the
activities of E-cadherin and N-cadherin chimeras, it has
been concluded that a 69 amino acid portion of the extra-
cellular domain of N-cadherin is necessary and sufficient to
promote an EMT in squamous epithelial cells [42]. In the
case of the BRI-JM01 cells, the presence of N-cadherin at
the cell surface was not sufficient to promote an EMT
because the untreated cells expressed surface N-cadherin,
yet maintained an epithelial-like cuboidal morphology. It
may be, however, that the basal expression of N-cadherin
in these cells predisposed them to undergo a TGF-β-
induced EMT. Evidently, there may be other genes, in
addition to N-cadherin, that are basally expressed in the
BRI-JM01 cells that are important for rendering them capa-
ble of exhibiting a TGF-β-induced EMT response in vitro.
We have evidence that this particular basal gene expres-
sion program probably arose because of genetic events
occurring during the development of the tumor, rather than
during immortalization in culture, because two other cell
lines independently isolated from the same tumor as the
BRI-JM01 cells exhibited the same characteristics with
respect to their TGF-β-induced EMT response.
Conclusion
In summary, we isolated three new mouse mammary tumor
cell lines, one of which undergoes a TGF-β-induced EMT
response. The EMT response of these BRI-JM01 cells
resembles that which occurs in the NMuMG cell line; how-
ever, in our hands it is much more homogeneous and syn-
chronous. We propose that the BRI-JM01 cells may serve
as a useful model, in addition to the NMuMG and EpH4 cell
lines, for studying the signal transduction pathways that
control the various steps that are involved in EMT. We are
currently analyzing cDNA microarray and proteome data
obtained from these cells to identify genes and proteinsBreast Cancer Research    Vol 6 No 5    Lenferink et al.
R529
with expression that is specifically associated with EMT.
The identification of these genes/proteins is essential for
improving our understanding of the role of the EMT process
in the progression of breast carcinomas.
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